COMMUNIQUÉS West-GlobeNewswire

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
01/07/2026
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 07:30 a.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“ Abivax ” or the “ Company ”), a [...]
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
01/07/2026
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris PARIS, France, 1 er juillet 2026 – 07h30 CEST – Abivax SA (Euronext Paris : FR0012333284 – ABVX) (« Abivax » ou la « Société [...]
Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment
01/07/2026
Press Release Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment NCX 470 New Drug Application (NDA) submitted to the U.S. Food and Drug [...]
Idorsia appoints Roland Wandeler as Chief Executive Officer
01/07/2026
Ad hoc announcement pursuant to Art. 53 LR Idorsia appoints Roland Wandeler as CEO – effective October 1, 2026 – an experienced biopharmaceutical executive combining scientific expertise with business acumen to [...]
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
01/07/2026
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License [...]
Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
01/07/2026
SAN DIEGO and TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based [...]
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
01/07/2026
$3 million upfront with up to approximately $5.8 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027; if [...]
Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
30/06/2026
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes. [...]
Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
30/06/2026
DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“ [...]
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
30/06/2026
Transaction Expected to Close July 2, 2026 FULLERTON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer [...]
Result of Annual General Meeting
30/06/2026
June 30, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of Annual General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company [...]
DLH Announces Leadership Transition
30/06/2026
Zach Parker to Retire; Kathryn JohnBull Appointed CEO; Steve Oroho Appointed CFO ATLANTA, June 30, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital [...]
Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
30/06/2026
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday, August 6, 2026, [...]
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
30/06/2026
Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides DUBLIN, Ireland and BRIDGEWATER, N. [...]
Acquisition of Own Shares
30/06/2026
Mechelen, Belgium; 30 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
Abivax annonce le lancement d’une offre au public d’American Depositary Shares
30/06/2026
Abivax annonce le lancement d’une offre au public d’American Depositary Shares PARIS, France – 30 juin 2026 – 22h45 CEST – Abivax SA (Euronext Paris : FR0012333284 – ABVX) (« Abivax » ou la « Société »), une société de [...]
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
30/06/2026
EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
30/06/2026
Company announcement No. 29 / 2026 Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. Copenhagen, Denmark, June 30, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
Total number of shares and voting rights in Zealand Pharma as of June 30, 2026
30/06/2026
Company announcement – No. 30 / 2026 Total number of shares and voting rights in Zealand Pharma as of June 30, 2026 Copenhagen, Denmark, June 30, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company") (Nasdaq: [...]

Pages